The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554

Anti-Cancer Drug Design

Volumn 11, Issue 3, 1996, Pages 231-242

  Aboagye, Eric O ^a   Lewis, Alexander D ^a,c   Graham, Martin A ^a,d   Tracy, Mike ^b   Kelson, Andrew B ^b   Ryan, Kenneth J ^b   Workman, Paul ^a,e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SRI INTERNATIONAL   (United States)

^c HERIOT WATT UNIVERSITY   (United Kingdom)

^d Alnwick Research Centre   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

2 nitroimidazoles; Drug design; MRS probe; Pharmacokinetics

Indexed keywords

2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG STABILITY; DRUG TOXICITY; DRUG TUMOR LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; FECES; FEMALE; HYDROGEN BOND; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CELL HYPOXIA; FEMALE; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MOLECULAR PROBES; NEOPLASM TRANSPLANTATION; NITROIMIDAZOLES; TISSUE DISTRIBUTION;

ANIMALIA; TRIFLUORO;

EID: 0029943231     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. ABOAGYE, E.O., GRAHAM, M.A., LEWIS, A.D., TRACY, M., KELSON, A.B. & WORKMAN, P. (1995). Development and validation of a solid phase extraction and high performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe SR-4554 in Balb/c mouse plasma. Journal of Chromatography B, 672, 125.
2. ADAMS, G.E. (1981). Hypoxia-mediated drugs for radiation and chemotherapy. Cancer, 48, 696.
3. ADAMS, G.E., CLARKE, E.D., GRAY, P., JACOBS, R.S., STRATFORD, I.J., WARDMAN, P. & WATTS, M.E. (1979). Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. International Journal of Radiation Biology, 35, 151.
4. BROWN, J.M. & WORKMAN, P. (1980). Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiation Research. 82, 171.
5. CHAPMAN, J.D. (1991). Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiotherapy and Oncology, Suppl. 20, 13.
6. CHAPMAN, J.D., BAER, K. & LEE, J. (1983). Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Research, 43. 1523.
7. DABROW, M.B., KATZ, H., O'DWYER, P.J., AFSHAR, C. & GLUSKER, J.P. (1993). Molecular dimensions and properties of N-[1-(2-hydroxyethyl)-2-nitro-1H-imidazol-1-yl] acetamide. Archives of Biochemistry and Biophysics, 302, 259.
8. D'ARGENIO,. D.Z. & SCHUMITZKY, A. (1979). A program package for simulation and parameter estimation in pharmacokinetic systems. Computer Programs in Biomedicine. 9, 115.
9. FLOCKHART, I.R., MALCOLM, S.L., MARTEN, T.R., PARKINS, C.S., RUANE, R.J. & TROUP, D. (1978). Some aspects of the metabolism of misonidazole. British Journal of Cancer, 37, 264.
10. GREENSTOCK, C.L., BIAGLOW, J.E. & DURAND, R.E. (1978). Effects of sensitizers on cell respiration: II. The effects of hypoxic cell sensitizers on oxygen utilization in cellular and chemical models. British Journal of Cancer, 37, 11.
11. KAGIYA, V.T., NISHIMOTO, S.I., WANG, J., ABE, M. & SASAI, K. (1992). Fluorine modification of nitroazole radiosensitizers for the enhancement of sensitizing activity with lowering toxicity: a pharmacokinetic characterization. International Journal of Radiation Oncology Biology Physics, 22, 601.
12. 19F magnetic resonance spectroscopy in vivo. International Journal of Radiation Oncology Biology Physics, 16, 925.
13. RALEIGN, J.A., FRANKO, A.J., TREIBER, E.O., LUNT, J.A. & ALLEN, P.S. (1986). Covalent binding of 3 fluorinated 2-nitroimidazole to EMT-6 tumors in BALB/c mice: Detection by F19 nuclear magnetic resonance at 2.3T. International Journal of Radiation Oncology Biology Physics, 12, 1243.
14. TWENTYMAN, P.R., FOX, N.E., WRIGHT, K.A., WORKMAN, P., BROADHURST, M.J., MARTIN, J.A. & BLEEHEN, N.M. (1986). The in vitro effects and cross-resistance patterns of some novel anthracyclines. British Journal of Cancer, 53, 585.
15. URTASUN, R.C., CHAPMAN, J.D., FELDSTEIN, M.L., BAND, R.P., RABIN, H.R., WILSON, A.F., MARYNOWSKI, B., STARREVELD, E. & SHNITKA, T. (1978). Peripheral neuropathy related to misonidazole: incidence and pathology. British Journal of Cancer, 37 (Suppl. III), 271.
16. WARDMAN, P. (1977). The use of nitroaromatic compounds as hypoxia cell radiosensitizers. Current Topics in Radiation Research, 11, 347.
17. WHITE, R.A.S. & WORKMAN, P. (1980). Pharmacokinetic and tumour-penetrating properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-9963) in dogs. British Journal of Cancer, 41, 268.
18. WHITE, R.A.s., WORKMAN, p. & BROWN, J.M. (1980). The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2555 in dog-hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiation Research, 84, 542.
19. WORKMAN, P. (1982). Lipophilicity and the pharmacokinetics of nitroimidazoles. In Advanced Topics on Radiosensitizers on Hypoxic Cells. Breccia. A., Rimondi, C. & Adam, G.E. (eds). p. 143. Plenum: New York.
20. WORKMAN, P. (1989). Optimized treatment modalities of hypoxic tumour cells. In Drug Delivery in Cancer Treatment II: Symptom Control, Cytokines, Chemotherapy. Domellof, L. (ed.), p. 79. Springer-Verlag: Berlin.
21. WORKMAN, P. & BROWN, J.M. (1981). Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemotherapy and Pharmacology, 6, 39.
22. WORKMAN, P., LITTLE, C.J., MARTEN, T.R., DALE, A.D., RUANE, R.J., FLOCKHART, I.R. & BLEEHEN, N.W. (1978). Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. Journal of Chromatography: Biomedical Applications, 145, 507.